ACADIA Pharmaceuticals Inc. (ACAD) Insider Trading Activity

NASDAQ$25.99
Market Cap
$4.4B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
409 of 892
Rank in Industry
238 of 510

ACAD Insider Trading Activity

ACAD Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$2,456,928
18
100

Related Transactions

GAROFALO ELIZABETH A.director
0
$0
2
$131,234
$-131,234
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
0
$0
6
$249,514
$-249,514
Brege Lauradirector
0
$0
1
$314,634
$-314,634
Daly James Mdirector
0
$0
1
$670,983
$-670,983
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
0
$0
8
$1.09M
$-1.09M

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Activity of ACADIA Pharmaceuticals Inc.

Over the last 12 months, insiders at ACADIA Pharmaceuticals Inc. have bought $0 and sold $2.46M worth of ACADIA Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at ACADIA Pharmaceuticals Inc. have bought $30.16M and sold $3.34M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 294,154 shares for transaction amount of $7.45M was made by BAKER BROS. ADVISORS LP () on 2023‑05‑24.

List of Insider Buy and Sell Transactions, ACADIA Pharmaceuticals Inc.

2025-11-18SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
10,262
0.006%
$23.69
$243,114
+12.14%
2025-11-18SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
4,084
0.0024%
$23.69
$96,754
+12.14%
2025-11-10SaleDaly James Mdirector
30,000
0.0176%
$22.37
$670,983
+19.66%
2025-09-15SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
3,498
0.002%
$23.65
$82,728
-2.78%
2025-09-02SaleGAROFALO ELIZABETH A.director
1,600
0.001%
$25.98
$41,560
-6.07%
2025-08-18SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
22,000
0.0131%
$25.18
$554,024
-2.11%
2025-06-04SaleBrege Lauradirector
14,446
0.0086%
$21.78
$314,634
+8.52%
2025-05-16SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
2,000
0.0013%
$25.00
$50,000
+4.49%
2025-05-16SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
4,000
0.0024%
$22.50
$90,000
+4.49%
2025-05-02SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
3,498
0.002%
$14.60
$51,071
+53.76%
2025-05-02SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
1,327
0.0008%
$14.60
$19,374
+53.76%
2025-04-08SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
2,708
0.0016%
$14.82
$40,133
+60.07%
2025-04-08SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
1,028
0.0006%
$14.82
$15,235
+60.07%
2025-03-26SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
3,171
0.0019%
$17.05
$54,066
+32.35%
2025-03-26SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
1,095
0.0007%
$17.05
$18,670
+32.35%
2025-03-05SaleGAROFALO ELIZABETH A.director
4,919
0.003%
$18.23
$89,673
+23.34%
2025-02-24SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
773
0.0005%
$19.96
$15,429
+14.14%
2025-02-24SaleKihara JamesPRINCIPAL ACCOUNTING OFFICER
475
0.0003%
$19.96
$9,481
+14.14%
2024-11-19SaleTeehan BrendanEVP, COO, HEAD OF COMMERCIAL
10,329
0.0065%
$16.81
$173,630
+28.04%
2024-11-19SaleSchneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
10,259
0.0064%
$16.81
$172,454
+28.04%
Total: 299
*Gray background shows transactions not older than one year

Insider Historical Profitability

19.44%
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER
53338
0.0315%
$1.39M023
GAROFALO ELIZABETH A.director
25382
0.015%
$659,678.1802
Kihara JamesPRINCIPAL ACCOUNTING OFFICER
25058
0.0148%
$651,257.42020
Brege Lauradirector
15095
0.0089%
$392,319.05013
Daly James Mdirector
4041
0.0024%
$105,025.5903
BAKER BROS. ADVISORS LP
39058564
23.0867%
$1.02B160
+14.48%
14159, L.P.
20278008
11.9859%
$527.03M10
+3.15%
BAKER FELIX
18001203
10.6402%
$467.85M40
+58.48%
OXFORD BIOSCIENCE PARTNERS IV LP10 percent owner
3160238
1.868%
$82.13M20
+29.7%
WALTON ALAN G
2573836
1.5213%
$66.89M10
+11.11%
van Osch Martiendirector
1168892
0.6909%
$30.38M20
+29.7%
GORDON CARL Ldirector
774006
0.4575%
$20.12M20
+29.7%
Brann Mark RPresident & CSO
317756
0.1878%
$8.26M09
DAVIS STEPHENCEO
186555
0.1103%
$4.85M030
Hacksell UliCEO
115549
0.0683%
$3M122
+11.11%
Baity GlennEVP AND GC
83734
0.0495%
$2.18M025
Teehan BrendanEVP, COO, HEAD OF COMMERCIAL
62105
0.0367%
$1.61M016
Stankovic Srdjan R.President
61234
0.0362%
$1.59M023
KIM AUSTIN D.EVP,General Counsel, Secretary
46901
0.0277%
$1.22M015
Iversen Leslie Ldirector
36127
0.0214%
$938,940.7314
Mills RogerEVP, DEVELOPMENT AND CMO
18550
0.011%
$482,114.5003
Ridloff ElenaEVP and CFO
10553
0.0062%
$274,272.4706
SOLAND DANIEL Bdirector
10000
0.0059%
$259,900.0020
<0.0001%
KAPLAN LESTER J PH Ddirector
8500
0.005%
$220,915.0003
Rasmussen Torstendirector
8500
0.005%
$220,915.0006
YANG MICHAEL J.EVP and CCO
8059
0.0048%
$209,453.4107
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER
1671
0.001%
$43,429.2904
HARRIGAN EDMUNDdirector
1000
0.0006%
$25,990.0010
<0.0001%
Miller Eric AlejandroController & PAO
270
0.0002%
$7,017.3003
BORER MICHAEL Tdirector
0
0%
$002
GRAY MARY ANNdirector
0
0%
$003
Aasen Thomas HEXEC VP, CFO AND CBO
0
0%
$0015
Lundstrom BrianSr. VP, Bus. Devt.
0
0%
$005
Wells William McDowalldirector
0
0%
$004
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$159,914,414
243
18.52%
$3.65B
$66,736,176
136
27.54%
$3.8B
$193,151,375
134
8.18%
$4.43B
$52,263,649
70
1.18%
$4.12B
$224,382,625
44
27.62%
$4.71B
$104,428,685
44
22.55%
$3.3B
ACADIA Pharmaceuticals Inc.
(ACAD)
$1,275,975,557
32
19.44%
$4.4B
$61,703,557
26
40.25%
$3.3B
$74,605,681
14
47.06%
$5.1B
$3,073,199
10
16.77%
$4.95B
$35,908,794
10
126.31%
$5.13B
$1,248,715
10
5.66%
$3.29B
$1,711,150
9
31.59%
$3.83B
$25,064,843
9
12.75%
$4.59B
$182,500,000
6
29.00%
$3.99B
$2,246,813
6
70.15%
$4.85B
$461,215
5
10.35%
$3.59B
$50,990,767
2
19.79%
$4.43B
$7,600,000
1
-4.05%
$4.41B

ACAD Institutional Investors: Active Positions

Increased Positions182+54.98%19M+11.53%
Decreased Positions147-44.41%18M-10.91%
New Positions59New6MNew
Sold Out Positions32Sold Out840,602Sold Out
Total Postitions366+10.57%169M+0.62%

ACAD Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Baker Bros. Advisors Lp$1.13M25.38%42.9M00%2025-09-30
Blackrock, Inc.$532,863.0011.99%20.27M-383,772-1.86%2025-09-30
Vanguard Group Inc$399,066.008.98%15.18M-84,869-0.56%2025-09-30
State Street Corp$190,746.004.29%7.26M+1M+17.44%2025-09-30
Rtw Investments, Lp$187,830.004.23%7.14M-2M-20.58%2025-09-30
Geode Capital Management, Llc$82,357.001.85%3.13M+108,547+3.59%2025-09-30
Dimensional Fund Advisors Lp$73,563.001.66%2.8M+402,534+16.8%2025-09-30
Adage Capital Partners Gp, L.L.C.$65,308.001.47%2.48M+2M+311.42%2025-09-30
Palo Alto Investors Lp$64,849.001.46%2.47M-96,525-3.77%2025-09-30
Braidwell Lp$62,535.001.41%2.38M+2MNew2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.